Crossmark

Complete Response in Metastatic Renal Cell Carcinoma with Nivolumab Re-challenge After First-Line IO + Tyrosine Kinase Inhibitors Therapy: a Case Report

Crossref DOI link: https://doi.org/10.1007/s42399-025-01977-2

Published Online: 2025-08-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yoshida, Takanori

Anai, Satoshi

Oyama, Nobuo

Fujimoto, Kiyohide
License Information

Text and Data Mining valid from 2025-08-06

Version of Record valid from 2025-08-06
More Information

Article History

Received: 8 February 2025

Revised: 24 June 2025

Accepted: 30 June 2025

First Online: 6 August 2025

Declarations

:

: Not applicable.

: Written informed consent was obtained from the patient for participation.

: Written informed consent was obtained from the patient for publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below